Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 297 publications
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.
Journal: Blood immunology & cellular therapy
Published: July 08, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.
Journal: Blood cancer journal
Published: February 24, 2026
A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Journal: Blood cancer journal
Published: January 27, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Journal: Blood cancer discovery
Published: January 20, 2026
Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.
Journal: Leukemia & lymphoma
Published: December 30, 2025
Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.
Journal: Haematologica
Published: December 19, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2025
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.
Journal: British journal of haematology
Published: October 12, 2025
Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].
Journal: Transplantation and cellular therapy
Published: October 09, 2025
Last Updated: 09/26/2026